Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERICA L MAYER

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1336121789
CMS profile
196667
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$85,449.17

52 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $81,677.91 25
Food and Beverage $1,894.20 19
Travel and Lodging $1,833.81 7
Education $43.25 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $21,000.00 4
AstraZeneca Pharmaceuticals LP $15,005.60 10
Genentech, Inc. $14,439.11 5
Novartis Pharmaceuticals Corporation $11,600.34 6
AstraZeneca UK Limited $7,664.02 11
F. Hoffmann-La Roche AG $6,150.00 3
Eli Lilly and Company $5,138.00 10
Genentech USA, Inc. $4,117.61 2
E.R. Squibb & Sons, L.L.C. $334.49 1

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERICA L MAYER

NPI 1336121789 · CMS profile ID 196667

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336121789?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERICA L MAYER, NPI 1336121789, CMS profile ID 196667. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336121789?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ERICA L MAYER, NPI 1336121789, CMS profile ID 196667. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336121789?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ERICA L MAYER, NPI 1336121789, CMS profile ID 196667, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1336121789?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

52 matching records · $85,449.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 52 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–52 of 52.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca UK Limited $685.0003/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202985906 CMS
AstraZeneca Pharmaceuticals LP $4,920.0002/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206593500 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,617.37 5
PY2020 $4,333.00 2
PY2021 $18,879.42 9
PY2022 $9,795.68 10
PY2023 $25,998.75 15
PY2024 $29,189.98 21
PY2025 $85,449.17 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,882.90 4
PY2025 Principal investigator $5,404,681.24 238
PY2024 Recipient $534,088.94 2
PY2024 Principal investigator $11,732,974.20 269
PY2023 Recipient $3,821.82 3
PY2023 Principal investigator $7,889,174.32 200
PY2022 Recipient $1,270.00 2
PY2022 Principal investigator $6,761,889.59 143
PY2021 Principal investigator $5,774,214.47 95
PY2020 Principal investigator $7,800,717.44 500
PY2019 Principal investigator $6,264,661.64 577

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

242 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721431
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721433
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721443
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721573
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721625
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721629
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721637
Principal investigator 1 PFIZER INC. $54.70 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721691
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721693
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721699
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721703
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721765
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721805
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721811
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721813
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721825
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721875
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721883
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721897
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721927
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721935
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721945
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722013
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722069
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722071
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722081
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722085
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722135
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722143
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722145
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722181
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722199
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722201
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722215
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722275
Principal investigator 1 PFIZER INC. $54.70 12/18/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722416
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $6,860.06 12/15/2025 Non-covered Recipient Entity
DANA-FARBER/MASS GENERAL BRIGHAM CANCER CARE, INC
ALI-1201 No dispute reported 06/30/2026 1251753972
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,865.16 12/12/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas No dispute reported 06/30/2026 1235997774
Recipient F. Hoffmann-La Roche AG $503.68 12/12/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211535681
Recipient F. Hoffmann-La Roche AG $292.89 12/12/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211535685
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,475.82 12/03/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE, INC
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185537978
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $11,575.80 11/14/2025 Non-covered Recipient Entity
DANA-FARBER/MASS GENERAL BRIGHAM CANCER CARE, INC
ALI-1201 No dispute reported 06/30/2026 1251753978
Recipient F. Hoffmann-La Roche AG $1,225.57 10/18/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211535676
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721631
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721777
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721891
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722554
Principal investigator 1 Genentech, Inc. $11,508.00 10/16/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594523
Principal investigator 1 Genentech, Inc. $3,000.00 10/16/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594527
Principal investigator 1 Genentech, Inc. $71,895.00 10/16/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594531
Principal investigator 1 Genentech, Inc. $2,275.00 10/16/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594535
Principal investigator 1 Genentech, Inc. $16,410.00 10/16/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594538
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721427
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721429
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721435
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721437
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721439
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721441
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721567
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721569
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721571
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721575
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721577
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721579
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721581
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721583
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721627
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721633
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721635
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721639
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721641
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721689
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721695
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721697
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721701
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721705
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721707
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721709
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721711
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721759
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721761
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721763
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721767
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721769
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721771
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721773
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721775
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721807
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721809
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721815
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721823
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721827
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721877
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721879
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721881
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721885
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721887
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721889
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721893
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721895
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721929
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721931
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721933
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721943
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721947
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721991
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721993
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721995
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721997
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721999
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722001
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722009
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722011
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722073
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722083
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722125
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722127
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722129
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722131
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722133
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722147
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722203
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722211
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722213
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722261
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722263
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722265
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722273
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722277
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722362
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722364
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722366
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722406
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722408
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722418
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722420
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722550
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722552
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722562
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722564
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722566
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,850.00 09/12/2025 Non-covered Recipient Entity
DANA FARBER PARTNERS CANCER CARE
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185537972
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $16,967.37 08/15/2025 Non-covered Recipient Entity
DANA-FARBER/MASS GENERAL BRIGHAM CANCER CARE, INC
ALI-1201 No dispute reported 06/30/2026 1251753974
Principal investigator 1 Genentech, Inc. $4,500.00 07/17/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594490
Principal investigator 1 Genentech, Inc. $143,790.00 07/17/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594499
Principal investigator 1 Genentech, Inc. $22,254.00 07/17/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594501
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,200.00 07/04/2025 Non-covered Recipient Entity
Dana-Farber Cancer Institute, Clinical Research Laboratory
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas No dispute reported 06/30/2026 1235997764
Principal investigator 1 GlaxoSmithKline, LLC. $45,303.84 06/27/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160818
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722688
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228724620
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784243
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784383
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784526
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785002
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785338
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785496
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785648
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785688
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228786841
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787120
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787142
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787150
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787453
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787794
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787872
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788110
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788206
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789041
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789254
Principal investigator 1 GlaxoSmithKline, LLC. $181,215.36 06/20/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160831
Principal investigator 1 GlaxoSmithKline, LLC. $45,303.84 06/19/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160822
Principal investigator 1 GlaxoSmithKline, LLC. $45,303.84 06/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192162421
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $57,350.00 06/16/2025 Non-covered Recipient Entity
DANA-FARBER/MASS GENERAL BRIGHAM CANCER CARE, INC
ALI-1201 No dispute reported 06/30/2026 1251753976
Principal investigator 1 Genentech, Inc. $816.00 06/11/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594322
Principal investigator 1 GlaxoSmithKline, LLC. $45,303.84 06/06/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160235
Principal investigator 1 PFIZER INC. $500.00 05/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228720101
Principal investigator 1 PFIZER INC. $500.00 05/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784262
Principal investigator 1 PFIZER INC. $500.00 05/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785192
Principal investigator 1 PFIZER INC. $500.00 05/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787192
Principal investigator 1 PFIZER INC. $500.00 05/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787772
Principal investigator 1 PFIZER INC. $500.00 05/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788027
Principal investigator 1 Genentech, Inc. $1,224.00 05/05/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594325
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $65,100.00 04/30/2025 Covered Recipient Teaching Hospital
Dana-Farber Cancer Institute
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas No dispute reported 06/30/2026 1236001379
Principal investigator 1 PFIZER INC. $500.00 04/29/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228719629
Principal investigator 1 PFIZER INC. $500.00 04/29/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784340
Principal investigator 1 PFIZER INC. $500.00 04/29/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785960
Principal investigator 1 PFIZER INC. $500.00 04/29/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789411
Principal investigator 1 AstraZeneca Pharmaceuticals LP $783,497.26 04/23/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC.
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185537980
Principal investigator 1 GlaxoSmithKline, LLC. $90,607.68 04/22/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160800
Principal investigator 1 GlaxoSmithKline, LLC. $23,588.76 04/22/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192162413
Principal investigator 1 GlaxoSmithKline, LLC. $618,536.00 04/04/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIV
A PHASE II STUDY OF NIRAPARIB WITH DOSTARLIMAB THERAPY AS NEOADJUVANT No dispute reported 06/30/2026 1192162445
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784269
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784530
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784588
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784882
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785350
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787628
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788569
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789395
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789730
Principal investigator 1 PFIZER INC. $500.00 04/02/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789773
Recipient E.R. Squibb & Sons, L.L.C. $860.76 03/28/2025 Covered Recipient Physician Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin No dispute reported 06/30/2026 1236002143
Principal investigator 1 Genentech, Inc. $32,909.00 03/24/2025 Non-covered Recipient Entity
DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211594320
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722954
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784522
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785834
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228786308
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228786860
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787358
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787620
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787754
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787758
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788727
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788740
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789383
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789392
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789415
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228790052
Principal investigator 1 GlaxoSmithKline, LLC. $135,911.52 03/11/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160810
Principal investigator 1 GlaxoSmithKline, LLC. $35,383.14 03/07/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160814
Principal investigator 1 GlaxoSmithKline, LLC. $1,237,073.00 03/05/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIV
A PHASE II STUDY OF NIRAPARIB WITH DOSTARLIMAB THERAPY AS NEOADJUVANT No dispute reported 06/30/2026 1192162440
Principal investigator 1 PFIZER INC. $569,887.95 02/24/2025 Non-covered Recipient Entity
DANA FARBER PARTNERS CANCER CARE
PALBOCICLIB AFTER CDK AND ENDOCRINE THERAPY PACEA RANDOMIZED PHASE II STUDY OF FULVESTRANT PALBOCICLIB AND AVELUMAB FOR ENDOCRINE PRETREATED ERHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228778804
Principal investigator 1 GlaxoSmithKline, LLC. $90,607.68 02/06/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160240
Principal investigator 1 GlaxoSmithKline, LLC. $226,519.20 02/05/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192162427
Principal investigator 1 GlaxoSmithKline, LLC. $35,383.14 02/04/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160827
Principal investigator 1 GlaxoSmithKline, LLC. $23,588.76 02/04/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192162417
Principal investigator 1 GlaxoSmithKline, LLC. $70,766.28 02/04/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192162436
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784518
Principal investigator 1 PFIZER INC. $600.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785009
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785021
Principal investigator 1 PFIZER INC. $600.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785119
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785636
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228786305
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787959
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788067
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788931
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789089
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Non-covered Recipient Entity
Dana FarberMass General Brigham CancerCare Inc
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789427
Principal investigator 1 AstraZeneca UK Limited $87,248.18 01/28/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE, INC
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185537974
Principal investigator 1 GlaxoSmithKline, LLC. $45,303.84 01/28/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192160805
Principal investigator 1 AstraZeneca Pharmaceuticals LP $187,629.86 01/24/2025 Non-covered Recipient Entity
DANA FARBER PARTNERS CANCER CARE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185537976
Principal investigator 1 GlaxoSmithKline, LLC. $181,215.36 01/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY
0000000000000000000000000000000000000000000000000000000000000000214387 No dispute reported 06/30/2026 1192162432